Literature DB >> 22350417

miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Kevin B Jones1, Zaidoun Salah, Sara Del Mare, Marco Galasso, Eugenio Gaudio, Gerard J Nuovo, Francesca Lovat, Kimberly LeBlanc, Jeff Palatini, R Lor Randall, Stefano Volinia, Gary S Stein, Carlo M Croce, Jane B Lian, Rami I Aqeilan.   

Abstract

Osteosarcoma remains a leading cause of cancer death in adolescents. Treatment paradigms and survival rates have not improved in two decades. Driving the lack of therapeutic inroads, the molecular etiology of osteosarcoma remains elusive. MicroRNAs (miRNAs) have demonstrated far-reaching effects on the cellular biology of development and cancer. Their role in osteosarcomagenesis remains largely unexplored. Here we identify for the first time an miRNA signature reflecting the pathogenesis of osteosarcoma from surgically procured samples from human patients. The signature includes high expression of miR-181a,miR-181b, and miR-181c as well as reduced expression of miR-16, miR-29b, and miR-142-5p. We also demonstrate that miR-181b and miR-29b exhibit restricted expression to distinct cell populations in the tumor tissue. Further, higher expression of miR-27a and miR-181c* in pre-treatment biopsy samples characterized patients who developed clinical metastatic disease. In addition, higher expression of miR-451 and miR-15b in pre-treatment samples correlated with subsequent positive response to chemotherapy. In vitro and in vivo functional validation in osteosarcoma cell lines confirmed the tumor suppressive role of miR-16 and the pro-metastatic role of miR-27a. Furthermore, predicted target genes for miR-16 and miR-27a were confirmed as down-regulated by real-time PCR. Affymetrix array profiling of cDNAs from the osteosarcoma specimens and controls were interrogated according to predicted targets of miR-16, miR142-5p, miR-29b, miR-181a/b, and miR-27a. This analysis revealed positive and negative correlations highlighting pathways of known importance to osteosarcoma, as well as novel genes. Thus, our findings establish a miRNA signature associated with pathogenesis of osteosarcoma as well as critical pre-treatment biomarkers of metastasis and responsiveness to therapy. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350417      PMCID: PMC3328547          DOI: 10.1158/0008-5472.CAN-11-2663

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program.

Authors:  Mohammad Q Hassan; Jonathan A R Gordon; Marcio M Beloti; Carlo M Croce; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-27       Impact factor: 11.205

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2.

Authors:  Hao Zhang; Xiaobing Cai; Yang Wang; Hao Tang; Daki Tong; Fang Ji
Journal:  Oncol Rep       Date:  2010-11       Impact factor: 3.906

4.  MicroRNA expression profiling using microarrays.

Authors:  Chang-Gong Liu; George Adrian Calin; Stefano Volinia; Carlo M Croce
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

5.  Modulation of mismatch repair and genomic stability by miR-155.

Authors:  Nicola Valeri; Pierluigi Gasparini; Muller Fabbri; Chiara Braconi; Angelo Veronese; Francesca Lovat; Brett Adair; Ivan Vannini; Francesca Fanini; Arianna Bottoni; Stefan Costinean; Sukhinder K Sandhu; Gerard J Nuovo; Hansjuerg Alder; Roberta Gafa; Federica Calore; Manuela Ferracin; Giovanni Lanza; Stefano Volinia; Massimo Negrini; Michael A McIlhatton; Dino Amadori; Richard Fishel; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

6.  Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.

Authors:  Ram Eitan; Michal Kushnir; Gila Lithwick-Yanai; Miriam Ben David; Moshe Hoshen; Marek Glezerman; Moshe Hod; Gad Sabah; Shai Rosenwald; Hanoch Levavi
Journal:  Gynecol Oncol       Date:  2009-05-14       Impact factor: 5.482

7.  A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway.

Authors:  Limei Qin; Yaosheng Chen; Yuna Niu; Weiquan Chen; Qiwei Wang; Shuqi Xiao; Anning Li; Ying Xie; Jing Li; Xiao Zhao; Zuyong He; Delin Mo
Journal:  BMC Genomics       Date:  2010-05-23       Impact factor: 3.969

8.  Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression.

Authors:  Qingmin Sun; Rihong Cong; Hongli Yan; Haijuan Gu; Ying Zeng; Nannan Liu; Jie Chen; Bin Wang
Journal:  Oncol Rep       Date:  2009-09       Impact factor: 3.906

9.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

10.  Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production.

Authors:  Aline Bozec; Latifa Bakiri; Maria Jimenez; Thorsten Schinke; Michael Amling; Erwin F Wagner
Journal:  J Cell Biol       Date:  2010-09-13       Impact factor: 10.539

View more
  187 in total

1.  MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients.

Authors:  Fei Zhang; Wei Huang; Meixia Sheng; Tielong Liu
Journal:  Tumour Biol       Date:  2014-11-13

2.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

3.  miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2.

Authors:  Zhengwen Sun; Tongqing Zhang; Huanyu Hong; Qingxia Liu; Haiguang Zhang
Journal:  Mol Cell Biochem       Date:  2014-08-26       Impact factor: 3.396

4.  Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study.

Authors:  Huading Lu; Lei Zhu; Liyi Lian; Mingwei Chen; Dehai Shi; Kun Wang
Journal:  Tumour Biol       Date:  2015-02-09

Review 5.  Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.

Authors:  Jonathan A R Gordon; Martin A Montecino; Rami I Aqeilan; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

Review 6.  Bone marrow stroma-derived miRNAs as regulators, biomarkers and therapeutic targets of bone metastasis.

Authors:  Maša Alečković; Yibin Kang
Journal:  Bonekey Rep       Date:  2015-04-15

7.  A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF.

Authors:  Kexiang Zhang; Chaoyue Zhang; Li Liu; Jiahui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

8.  MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1.

Authors:  Guoqing Duan; Chunfeng Ren; Yuanmin Zhang; Shiqing Feng
Journal:  Tumour Biol       Date:  2015-03-12

9.  Association between interleukin 8 -251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case-control study.

Authors:  Yang Chen; Yang Yang; Song Liu; Shaowen Zhu; Hongfeng Jiang; Jinmin Ding
Journal:  Tumour Biol       Date:  2015-11-28

10.  MiR-374a promotes the proliferation of osteosarcoma cell proliferation by targeting Axin2.

Authors:  Tan Lu; Chao Zhang; Ming-Xiang Chai; Yong-Bo An; Jin-Ling Jia
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.